Pharmaceuticals 2011, 4(1), 91-100; doi:10.3390/ph4010091

Molecular Therapies in Thyroid Cancer

Northwestern University, Feinberg School of Medicine, Division of Hematology/ Oncology, Department of Medicine, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA
* Author to whom correspondence should be addressed.
Received: 2 November 2010; in revised form: 9 December 2010 / Accepted: 22 December 2010 / Published: 24 December 2010
(This article belongs to the Special Issue Targeted Therapy)
PDF Full-text Download PDF Full-Text [53 KB, uploaded 27 December 2010 09:32 CET]
Abstract: Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer.
Keywords: advanced thyroid cancer; molecular therapy; tyrosine kinase inhibitors

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Huyck, T.; Agulnik, M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011, 4, 91-100.

AMA Style

Huyck T, Agulnik M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals. 2011; 4(1):91-100.

Chicago/Turabian Style

Huyck, Timothy; Agulnik, Mark. 2011. "Molecular Therapies in Thyroid Cancer." Pharmaceuticals 4, no. 1: 91-100.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert